Trial Profile
Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Sep 2021
Price :
$35
*
At a glance
- Drugs Peficitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms RAJ4
- Sponsors Astellas Pharma
- 24 Aug 2021 Results of post-hoc analysis (RAJ3 & RAJ4) assessing the effect of peficitinib on patient- and physician-reported outcomes in Asian patients with RA and an inadequate response to prior disease-modifying antirheumatic drugs, published in the Arthritis Research and Therapy.
- 26 Jul 2019 Results assessing efficacy and safety of two dosage regimens of peficitinib in combination with MTX, compared with placebo, in Japanese patients with RA published in the Annals of the Rheumatic Diseases
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism